Trial Profile
A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin; Ezetimibe; Rosuvastatin; Simvastatin
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms ODYSSEY EAST
- Sponsors Sanofi
- 18 Nov 2019 Primary endpoint (Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) Analysis) has been met, according to results presented at the American Heart Association Scientific Sessions 2019
- 18 Nov 2019 Results assessing alirocumab efficacy and safety in patients with hypercholesterolemia at high cardiovascular risk were presented at the American Heart Association Scientific Sessions 2019
- 13 Aug 2018 Status changed from active, no longer recruiting to completed.